SCHEMBL10115015

SCHEMBL10115015

COc1ccc(Cl)cc1NC(=O)CCCCNS(=O)(=O)C(C)(C)C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.58
MEN1 O00255 4/20 0.58
POLB P06746 4/20 0.58
HPGD P15428 1/20 0.55
ALDH1A1 P00352 6/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
PSMD14 O00487 1/20 0.54
APAF1 O14727 1/20 0.54
GRK2 P25098 1/20 0.54
BCL2L1 Q07817 1/20 0.54
MCL1 Q07820 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.54
NPC1 O15118 1/20 0.52
CYP1A2 P05177 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP3A4 P08684 1/20 0.51
LMNA P02545 2/20 0.50
TSHR P16473 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10115234 0.85 MEN1 (0.58) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL10113181 0.84 CACNA1G (0.47) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL13566038 0.83 L3MBTL1 (0.47) KMT2AMEN1ALDH1A1NPC1CYP1A2
SCHEMBL10115018 0.83 MEN1 (0.58) KMT2AMEN1POLBHPGDALDH1A1
SCHEMBL10115075 0.81 NPC1 (0.56) ALDH1A1SMN1; SMN2NPC1CYP1A2CYP2C19
SCHEMBL10114991 0.79 ALDH1A1 (0.54) KMT2AMEN1POLBALDH1A1LMNA
SCHEMBL10113183 0.78 EPHX2 (0.54) KMT2AMEN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL10115017 0.78 F2 (0.46) KMT2AMEN1POLBALDH1A1SMN1; SMN2
SCHEMBL10113641 0.77 ALDH1A1 (0.48) KMT2AMEN1POLBALDH1A1SMN1; SMN2
SCHEMBL9468747 0.76 KMT2A (0.82) KMT2AMEN1POLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R KMT2A 2912/4885MEN1 2876/4885POLB 4727/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KMT2A 2768/4885MEN1 2932/4885POLB 4751/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KMT2A 2953/4885MEN1 2926/4885POLB 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.